Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

FDA approves first new clot-dissolving drug for ischemic stroke in decades
Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.
Cardiologists recommend complete revascularization, intravascular imaging in new ACS guidelines
The American College of Cardiology and American Heart Association published the new guidelines with assistance from other leading U.S. medical societies.
Why cardiac CT adoption remains low among primary care providers
The rapid rise of CCTA represents one of cardiology’s biggest ongoing trends, but most primary care providers are still not embracing a CT-first strategy.
Medtronic enrolls first patient in new coronary DCB trial—data could lead to FDA approval
The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan.
AI leader Heartflow enters new era focused on delivering personalized care for CAD patients
The company's AI-powered CCTA assessments have already been used to help manage more than 400,000 heart patients around the world.

FDA approves first new clot-dissolving drug for ischemic stroke in decades

Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.

Cardiologists recommend complete revascularization, intravascular imaging in new ACS guidelines

The American College of Cardiology and American Heart Association published the new guidelines with assistance from other leading U.S. medical societies.

Why cardiac CT adoption remains low among primary care providers

The rapid rise of CCTA represents one of cardiology’s biggest ongoing trends, but most primary care providers are still not embracing a CT-first strategy.

Medtronic enrolls first patient in new coronary DCB trial—data could lead to FDA approval

The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan.

Heartflow artificial intelligence CCTA images

AI leader Heartflow enters new era focused on delivering personalized care for CAD patients

The company's AI-powered CCTA assessments have already been used to help manage more than 400,000 heart patients around the world.

Aspartame linked to surging insulin levels, fatty plaques and inflammation

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Sotagliflozin the first drug of its kind to limit heart attacks, strokes in high-risk patients

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients.

Veterans with heart disease often receive better care through VA than they would elsewhere

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.